Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nanite
AddedFeb 15, 2024
UpdatedJun 18, 2026
Nanite

Nanite

Seed

Nanite: A next-gen, AI-driven non-viral gene delivery company using programmable polymer nanoparticles.

HQ
Boston, MA, US
Founded
2021
Overview
Compare
Fundraising
Employees
Website

Nanite, founded with a mission to revolutionize gene therapy, focuses on developing next-generation non-viral gene delivery systems. The company leverages its AI-driven platform, SAYER, to create programmable polymer nanoparticles designed for tissue-specific delivery across various medical modalities and indications. Nanite aims to provide safer and more efficient alternatives to viral vectors, addressing critical needs in gene therapy for diseases like cystic fibrosis and HIV.

Notable affiliations include collaborations with the Cystic Fibrosis Foundation and funding from the Bill & Melinda Gates Foundation. Key achievements include securing a $1.8 million award for HIV gene therapy research. Nanite's innovative approach has positioned it as a leader in the non-viral gene delivery space, promising significant advancements in the treatment of genetic disorders and enhancing the overall impact of gene therapy.

Nanite - Similar Companies

Nanotransfer logo

Nanotransfer

nanotransfer.bio

Mana.bio logo

Mana.bio

mana.bio

Envoya logo

Envoya

envoyabio.com

Lattice Therapeutics logo

Lattice Therapeutics

Nano Cures logo

Nano Cures

nanocures.com

SalioGen Therapeutics logo

SalioGen Therapeutics

saliogen.com

Code Biotherapeutics logo

Code Biotherapeutics

codebiotx.com

Apertura Gene Therapy logo

Apertura Gene Therapy

aperturagtx.com

Atom Bioworks logo

Atom Bioworks

atombioworks.com

20n logo

20n

NeuroX1 logo

NeuroX1

neurox1.com

Nanobiofab logo

Nanobiofab

nanobiofab.com

GEn1E Lifesciences logo

GEn1E Lifesciences

gen1e.com

Strm.Bio logo

Strm.Bio

strm.bio

NExTNet logo

NExTNet

nextnetinc.com

Nanite - Quick Facts

Who are Nanite's competitors?

Companies similar to Nanite include Nanotransfer, Mana.bio, Envoya and Lattice Therapeutics.

When was Nanite founded?

Nanite was founded in 2021.

Where is Nanite's headquarters located?

Nanite's headquarters is located in Boston, MA, US.

When was Nanite's last funding round?

Nanite's most recent funding round was for $2M (USD) in March 2023.

How much has Nanite raised to-date?

As of Mar 15, 2023, Nanite has raised a total of $8M (USD).

How many employees does Nanite have?

Nanite has 14 employees as of Feb 4, 2024.

Nanite - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Gene Delivery
Tags
  • Biotech
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software